Autoimmune gastritis
Conditions
Interventions
None listed
Sponsors
Kakogawa Central City Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who submitted the consent form of this study after establishment of diagnosis as having corpus dominant atrophy on endoscopy
Exclusion criteria
Exclusion criteria: The patients who are prescribed proton pomp inhibitor or vonoprazan fumarate or who are enabled to discontinue the drugs earlier than 1 month before endoscopic examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoscopic findings, Pathological findings, titer of anti-parietal cell antibody, existence of anti-intrinsic factor antibody and existence of Helicobacter pylori infection at the first diagnose establishment year and 1 year, 2 years, 3 years, 4 years and 5 years after the first year | — |
Secondary
| Measure | Time frame |
|---|---|
| Existence of accompanied diseases: neuroendocrine cell tumor, gastric cancer, anemia, autoimmune diseases (thyroid diseases, Type1 diabetes, Sjogren's syndrome and other autoimmune diseases), pepsinogen (PG) 1, PG 2 and PG 1/2 at the first diagnose establishment year and 1 year, 2 years, 3 years, 4 years and 5 years after the first year | — |
Countries
Japan
Contacts
Public ContactNoriko Kakinoki
Kakogawa Central City Hospital Clinical study and trial center
Outcome results
None listed